

## TargED Biopharmaceuticals appoints Emile van Corven as Vice President Chemistry Manufacturing & Control (VP CMC)

July 28, 2022

Utrecht, the Netherlands

TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, is very pleased to announce the appointment of Emile van Corven as their Vice President Chemistry Manufacturing & Control (CMC).

Kristof Vercruysse, CEO of TargED commented: “We are delighted that Emile is joining our team as Vice President CMC. Since closing our Series A investment in February 2022, we are rapidly expanding our team with seasoned biotech experts. In Emile, we found the ideal candidate to improve and standardize the production process of our lead compound, Microlyse. He has ample experience in developing a variety of biotechnological agents from the R&D-phase all the way into the commercial-phase. His extensive experience and outstanding track record in the development of new medicinal products will be a valuable asset for TargED Biopharmaceuticals.”

### **About Emile van Corven**

Emile obtained his Masters degree in Biology/Biochemistry in 1983 from the University of Leiden, Netherlands. He obtained his PhD in 1987, and was a postdoctoral researcher at the Netherlands Cancer Institute in Amsterdam, Netherlands. He decided to enter the biopharmaceutical industry in 1992. He fulfilled several positions with increasing responsibility, up to Chief Development Officer/Managing Director, in the development of complex bio-pharmaceuticals, esp. recombinant proteins (Pharming BV), monoclonal antibodies (Polpharma Biologics), viral vaccines (Crucell/J&J) and gene therapy vectors (uniQure). With more than 30 years of Biotech experience, Emile finally decided to start as an independent consultant in April 2022.

Emile van Corven stated: “I am excited to join the enthusiastic TargED team. The Microlyse product has huge potential in the treatment of various thrombotic diseases. I want to make sure the product reaches clinical trials and, eventually, the market.”

### **About TargED Biopharmaceuticals**

TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020 by Associate Professor at the Department of Clinical Chemistry and Haematology, Coen Maas, PhD, an expert in thrombosis and hemostasis, Steven de Maat, PhD, an expert in recombinant protein development and optimization, Marc van Moorsel, researcher with focus on Acute Ischemic Stroke and Kristof Vercruysse, with more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013.

Contact: [info@targedbio.com](mailto:info@targedbio.com)

[www.targedbiopharmaceuticals.com](http://www.targedbiopharmaceuticals.com)  
[www.linkedin.com/company/targedbiopharmaceuticals/](https://www.linkedin.com/company/targedbiopharmaceuticals/)